Skip to main navigation Skip to search Skip to main content

Bifidobacterium animalis subsp. lactis Bi-07 contributes to increasing lactose digestion: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

  • Dominique Turck
  • , Jacqueline Castenmiller
  • , Stefaan De Henauw
  • , Karen Ildico Hirsch-Ernst
  • , John Kearney
  • , Helle Katrine Knutsen
  • , Alexandre Maciuk
  • , Inge Mangelsdorf
  • , Harry J. McArdle
  • , Androniki Naska
  • , Carmen Pelaez
  • , Kristina Pentieva
  • , Frank Thies
  • , Sophia Tsabouri
  • , Marco Vinceti
  • , Jean Loui s Bresson
  • , Alfonso Siani

Research output: Contribution to journalArticlepeer-review

Abstract

Following an application from DuPont Nutrition Biosciences ApS submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Bifidobacterium animalis subsp. lactis Bi-07 (Bi-07) and contribution to increasing lactose digestion. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is Bi-07. The Panel considers that Bi-07 is sufficiently characterised. The claimed effect proposed by the applicant is ‘improvement of lactose digestion’. The Panel considers that increasing lactose digestion is a beneficial physiological effect for individuals with lactose maldigestion provided that the symptoms of lactose maldigestion are improved. Two human intervention studies which investigated a single dose effect of Bi-07 on lactose digestion using the hydrogen breath test, as well as on gastrointestinal symptoms were submitted. These studies show that consumption of Bi-07 (1012 CFU) increases lactose digestion in individuals with lactose maldigestion and that Bi-07 exhibits lactase activity in vitro. However, these studies provide no evidence that increasing lactose digestion through the consumption of Bi-07 (1012 CFU) improves gastrointestinal symptoms of lactose maldigestion, which is considered a beneficial physiological effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of Bifidobacterium animalis subsp. lactis Bi-07 and a beneficial physiological effect (i.e. the improvement of symptoms of lactose maldigestion) in individuals with lactose maldigestion.

Original languageEnglish
Article numbere06198
JournalEFSA Journal
Volume18
Issue number7
DOIs
Publication statusPublished - 1 Jul 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bifidobacterium animalis subsp. lactis Bi-07
  • health claim
  • lactase
  • lactose maldigestion

Fingerprint

Dive into the research topics of 'Bifidobacterium animalis subsp. lactis Bi-07 contributes to increasing lactose digestion: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006'. Together they form a unique fingerprint.

Cite this